// App-Quantinova.ai

POS0646 (2021) : RAPID AND CONCURRENT IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES OF RHEUMATOID ARTHRITIS WITH BARICITINIB IN RA-BEAM

Researchers

Presenter

  • V. Strand

Principal Investigators

  • A. Sebba

  • B. Jia

  • J. Birt

  • A. Quebe

  • H. Zhang

  • P. C. Taylor

Medical Centers

  • Stanford University School of Medicine, Division of Immunology/Rheumatology, Palo Alto, United States of America

  • University of South Florida, Department of Rheumatology, Tampa, United States of America

  • Eli Lilly & Co., Lilly Research Labs, Indianapolis, United States of America

  • TechData Services, Statistics, King of Prussia, United States of America

  • Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford University, The Kennedy Institute of Rheumatology, Oxford, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Baricitinib

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • NCT01710358

Sponsors

  • Celgene

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved